Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-01-08
2008-12-23
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S138100, C424S145100, C424S155100
Reexamination Certificate
active
07468184
ABSTRACT:
The invention relates to a therapeutic agent for cachexia comprising, as an active ingredient, a substance capable of inhibiting the binding between a parathyroid hormone related protein (PTHrP) and a receptor thereof.
REFERENCES:
patent: 4771124 (1988-09-01), Rosenblatt et al.
patent: 5001223 (1991-03-01), Rosenblatt et al.
patent: 5217896 (1993-06-01), Kramer et al.
patent: 5626845 (1997-05-01), Yoneda et al.
patent: 5849695 (1998-12-01), Cohen et al.
patent: 5993817 (1999-11-01), Yoneda et al.
patent: 0 293 130 (1988-11-01), None
patent: 0293 158 (1988-11-01), None
patent: 0 449 405 (1991-10-01), None
patent: 0 811 383 (1997-12-01), None
patent: 0 878 201 (1998-11-01), None
patent: 0 962 467 (1999-12-01), None
patent: 0962467 (1999-12-01), None
patent: 1 004 313 (2000-05-01), None
patent: 1 090 643 (2001-04-01), None
patent: 2-207099 (1990-08-01), None
patent: 4-502408 (1992-05-01), None
patent: 4-228089 (1992-08-01), None
patent: 7-165790 (1995-06-01), None
patent: 7-316195 (1995-12-01), None
patent: 11-80025 (1999-03-01), None
patent: 11-222440 (1999-08-01), None
patent: 2000-080100 (2000-03-01), None
patent: WO 89/11297 (1989-11-01), None
patent: WO 89/11298 (1989-11-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/16928 (1991-11-01), None
patent: WO 92/00753 (1992-01-01), None
patent: WO 92/17602 (1992-10-01), None
patent: WO 92/19759 (1992-11-01), None
patent: WO 93/13133 (1993-07-01), None
patent: WO 94/11523 (1994-05-01), None
patent: WO 96/03437 (1996-02-01), None
patent: WO 96/39184 (1996-02-01), None
patent: WO 96/22790 (1996-08-01), None
patent: WO 9622790 (1996-08-01), None
patent: WO 96/26737 (1996-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 98/13388 (1998-04-01), None
patent: WO 9813388 (1998-04-01), None
patent: WO 98/51329 (1998-11-01), None
patent: WO 99/57139 (1999-11-01), None
patent: WO 00/00219 (2000-01-01), None
Paul ( Fundamental Immunology, 3rd Edition, 1993. pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”).
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982).
Bendig (Methods: A Companion to Methods in Enzymology 1995; 8:83-93).
Hashimoto et al. (Clin. Cancer Res. 2007; 12: 292-298).
Rodenburg et al. (Hybridoma 1998; 17: 1-8).
U.S. Appl. No. 09/269,332, filed Mar. 25, 1999, Sato et al.
Abou-Samra et al., Expression Cloning of a Common Receptor for Parathyroid Hormone and Parathyroid Hormone-Related Peptide from Rat Osteoblast-Like Cells: A Single Receptor Stimulates Intracellular Accumulation of Both cAMP and Inositol Trisphosphates and Increases Intracellular Free Calcium,Proceedings of the National Academy of Sciences, 89:2732-2736 (1992).
Baba, PTH/PTHrP,Clinical Calcium, 5:97-101 (1995) (English Translation).
Beck, S.A., et al., Lipolytic Factors Associated with Murine and Human Cancer Cachexia,Journal of the National Cancer Institute, 82:1922-1926 (1990).
Belyavsky et al., PCR-Based cDNA Library Construction: General cDNA Libraries at the Level of a Few Cells,Nucleic Acids Research, 17:2919-2933 (1989).
Benet et al, “Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination,” In:The Pharmacological Basis of Therapeutics, 8thedition, pp. 3-32 (1990).
Burtis, Parathyroid Hormone-Related Protein: Structure: Function, and Measurement,Clinical Chemistry, 38:2171-2183 (1992).
Carter et al. Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,Proceedings of the National Academy of Sciences, 89:4285-4289 (1992).
Chirgwin et al., Isolation of Biologically Active Ribonucleic Acid From Sources Enriched in Ribonuclease,Biochemistry, 18:5294-5299 (1979).
Chomczynsk et al., Single-Step Method of RNA Isolation By Acid Guanidinum Thiocyanate-Phenol-Chloroform Extraction,Analytical Biochemistry, 162:156-159 (1987).
Chothia, Canonical Structures for the Hypervariable Regions of Immunoglobulins,Journal of Molecular Biology, 196:901-917 (1987).
Co et al., Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen,The Journal of Immunology, 148:1149-1154 (1992).
Co et al., Humanized Antibodies for Antiviral Therapy,Proceedings of the National Academy of Science, 88:2869-2873 (1991).
Coleman et al., Biochemical Mechanisms of Parathyroid Hormone Action,The Parathyroids, Basic and Clinical Concepts, 239-258 (1994).
Cuisinier et al., Mechanisms That Generate Human Immunoglobulin Diversity Operate From the 8thWeek of Gestation in Fetal Liver,European Journal of Immunology, 23:110-118 (1993).
Dariavach et al., Human Immunoglobulin Cλ6 Gene Encodes the kern+Oz λ Chain and Cλ4 andCλ5 are Pseudogenes,Proceedings of the National Academy of Sciences, 84:9078 (1987).
Deftos et al., Utilization of a Potentially Universal Downstream Primer in the Rapid Identification and Charaterization of Vλ Genes From Two New Human Vλ Families,Scandinavian Journal of Immunology, 39:95-103 (1994).
de St. Groth, et al., Production of Monoclonal Antibodies: Strategy and Tactics,Journal of Immunological Methods, 35:1-21 (1980).
Dworkin, et al., Dietary Intake in Patients with Acquired Immunodeficiency Syndrome (AIDS), Patients with AIDS-Related Complex, and Serologically Positive Human Immunodeficiency Virus Patients: Correlations with Nutritional Status,Journal of Parenteral and Enteral Nutrition, 14:605-609 (1990).
Farmer et al., Speculations on the Design of Nonpeptidic Peptidomimetics,TIPS, 4:362-365 (1982).
Frohman et al., Rapid Production of Full-Length cDNAs From Rare Transcripts: Amplification Using a Single Gene-Specific Oligonucleotide Primer,Proceedings of the National Academy of Sciences, 85:8998-9002 (1988).
Galfrèet al., Rat x Rat Hybrid Myelomas and A Monoclonal Anti-Fd Portion of Mouse IgG,Nature, 277:131-133 (1979).
Gorman et al., Reshaping a Therapeutic CD4 Antibody,Proceedings of the National Academy of Sciences, 88:4181-4185 (1991).
Hammond, M., et al., Respiratory Muscle Strength in Congestive Heart Failure,Chest, 98:1091-1094 (1990).
Hardman, J.G. et al., (ed.), Goodman & Gilman's, “The Pharmacological Basis of Therapeutics”, Section XIII, Hormones and Hormone Anatgonists, McGraw-Hill Co. (USA) 9thed., at. 1528-1529, (1995).
Hardman, J.G., et al. (ed.), “Agents Affecting Calcification and Bone Turnover” in Goodman and Gilman's “The Pharmacological Basis of Therapeutics”, McGraw-Hill Co. (USA) 9thed., at 1523-1524 (1995).
Harris et al., Therapeutic Antibodies—The Coming of Age, TIBTECH, 11:42-44 (1993).
Ikeda, “Development of Novel Endocrinotherapy Targeting Cancer and Paraneoplastic Syndromes,” Progress in Clinical Pharmacology, 16:155-161 (1995) (English Abstract).
Jones et al., Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions,Bio/Technology, 9:88-89 (1991).
Jüppner et la., A G Protein-Linked Receptor for Parathyroid Hormone and Parathyroid Hormone-Related Peptide,Science, 254:1024-1026 (1991).
Kaji, H. et al., “Role of Dual Signal Transduction Systems in the Stimulation of Bone Resorption by Parathyroid Hormone-Related Peptide, The Direct Involvement of cAMP-Dependent Protein Kinase,”Horm. Metab. Res. 25:421-424 (1993).
Kajimura, N., et al., Toxohormones Responsible for Cancer Cachexia Syndrome in Nude Mice Bearing Human Cancer Cell Lines, Cancer Chemother Pharmacol, 38:S48-S52 (1996).
Karlsson et al., Kinetic Analysis of Monoclonal Antibody-Antigen Interactions with a New Biosensor Based Analytical System,Journal of ImmunologicalMethods, 145:229-240 (1991).
Kato, A., et al. “Incisor Change Induced by Excessive PTHrP in Rats,” Abstracts of 16thMeeting of Japanese Society of Toxicologic Pathology, p. 17 (2000) (English Translation).
Kearney et al., A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression But Permits the Construction of Antibody-Secreting Hybrid Cell Lines,The Journal of Immunology, 123:1548-1550 (1979).
Kemp et al., Parathyroid Hormone-Related Protein of Malignancy: Active Synthetic Fragments,Science238:1568-1570 (1987).
Kettleb
Ishii Kimie
Sato Koh
Tsunenari Toshiaki
Chugai Seiyaku Kabushiki Kaisha
Fetterolf Brandon J
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Therapeutic agent for cachexia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for cachexia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for cachexia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021129